Antibody Responses after SARS-CoV-2 Vaccination in Patients with Liver Diseases.
Antibody Responses after SARS-CoV-2 Vaccination in Patients with Liver Diseases.
复制标题
DOI：
10.3390/v14020207
复制
发表时间：
2022-01-21
期刊：
影响因子：
--
通讯作者：
Androutsakos T
中科院分区：
文献类型：
--
作者：
Bakasis AD;Bitzogli K;Mouziouras D;Pouliakis A;Roumpoutsou M;Goules AV;Androutsakos T
针对SARS-CoV-2的新型mrna疫苗显示出令人鼓舞的安全性和有效性。然而，关于它们在肝病（PWLD）患者（特别是肝硬化患者）中的免疫原性和安全性的数据缺乏。我们前瞻性地评估了完全接种PWLD （n = 87）和对照组（n = 40）的抗sars - cov -2 S-spike IgG抗体和中和活性。肝硬化PWLD血清转化率为97.4%(37/38)，非肝硬化PWLD为87.8%(43/49)，对照组为100%（40/40）。在肝硬化患者、非肝硬化患者和对照组中，分别有92.1%（35/38）、87.8%（43/49）和100%（40/40）检测到足够的中和活性。在多变量分析中，免疫抑制治疗与抗sars - cov -2抗体滴度（系数（SE）：−2.716 (0.634),p < 0.001）和中和活性（系数（SE）：−24.379 (4.582),p < 0.001）呈负相关，而年龄仅与中和活性呈负相关（系数（SE）：−0.31(0.14),p = 0.028）。接种疫苗约3个月后，共对52例有应答的PWLD进行了重新评估，未发现肝硬化PWLD和非肝硬化PWLD在体液应答方面存在差异。接种疫苗后未发现明显的副作用，在6个月的随访期间未报告有症状的突破性感染。总的来说，我们的研究表明，基于m- rna的SARS-CoV-2疫苗在PWLD中是安全有效的。然而，接受免疫抑制治疗的PWLD和高龄的PWLD在接种疫苗后可能应该更密切地监测。
The novel mRNA-based vaccines against SARS-CoV-2 display encouraging safety and efficacy profiles. However, there is a paucity of data regarding their immunogenicity and safety in patients with liver diseases (PWLD), especially in those with cirrhosis. We prospectively assessed anti-SARS-CoV-2 S-spike IgG antibodies and neutralizing activity in fully vaccinated PWLD (n = 87) and controls (n = 40). Seroconversion rates were 97.4% (37/38) in cirrhotic PWLD, 87.8% (43/49) in non-cirrhotic PWLD and 100% (40/40) in controls. Adequate neutralizing activity was detected in 92.1% (35/38), 87.8% (43/49) and 100% (40/40) of cirrhotics, non-cirrhotics and controls, respectively. On multivariable analysis, immunosuppressive treatment was negatively correlated with anti-SARS-CoV-2 antibody titers (coefficient (SE): −2.716 (0.634), p < 0.001) and neutralizing activity (coefficient (SE): −24.379 (4.582), p < 0.001), while age was negatively correlated only with neutralizing activity (coefficient (SE): −0.31(0.14), p = 0.028). A total of 52 responder PWLD were reassessed approximately 3 months post-vaccination and no differences were detected in humoral responses between cirrhotic and non-cirrhotic PWLD. No significant side effects were noted post vaccination, while no symptomatic breakthrough infections were reported during a 6-month follow up. Overall, our study shows that m-RNA-based SARS-CoV-2 vaccines are safe and efficacious in PWLD. However, PWLD under immunosuppressive treatment and those of advanced age should probably be more closely monitored after vaccination.
登录
查看更多内容
甲氨蝶呤会在免疫介导的炎症性疾病中对BNT162B2 mRNA Covid-19疫苗的免疫原性。
影响因子：
27.4
作者：
Haberman RH;Herati R;Simon D;Samanovic M;Blank RB;Tuen M;Koralov SB;Atreya R;Tascilar K;Allen JR;Castillo R;Cornelius AR;Rackoff P;Solomon G;Adhikari S;Azar N;Rosenthal P;Izmirly P;Samuels J;Golden B;Reddy SM;Neurath MF;Abramson SB;Schett G;Mulligan MJ;Scher JU
通讯作者：
Scher JU
BNT162B2 mRNA COVID-19疫苗的安全性和功效。
DOI：
10.1056/nejmoa2034577
发表时间：
2020-12-31
期刊：
The New England journal of medicine
影响因子：
--
作者：
Polack FP;Thomas SJ;Kitchin N;Absalon J;Gurtman A;Lockhart S;Perez JL;Pérez Marc G;Moreira ED;Zerbini C;Bailey R;Swanson KA;Roychoudhury S;Koury K;Li P;Kalina WV;Cooper D;Frenck RW Jr;Hammitt LL;Türeci Ö;Nell H;Schaefer A;Ünal S;Tresnan DB;Mather S;Dormitzer PR;Şahin U;Jansen KU;Gruber WC;C4591001 Clinical Trial Group
通讯作者：
C4591001 Clinical Trial Group
影响因子：
7.8
作者：
Ferrari D;Clementi N;Criscuolo E;Ambrosi A;Corea F;Di Resta C;Tomaiuolo R;Mancini N;Locatelli M;Plebani M;Banfi G
通讯作者：
Banfi G
影响因子：
25.7
作者：
Rabinowich L;Grupper A;Baruch R;Ben-Yehoyada M;Halperin T;Turner D;Katchman E;Levi S;Houri I;Lubezky N;Shibolet O;Katchman H
通讯作者：
Katchman H
影响因子：
6.4
作者：
McCashland, TM;Preheim, LC;Gentry-Nielsen, MJ
通讯作者：
Gentry-Nielsen, MJ